Investor relations

Investor Summary

SOMAÍ Pharmaceuticals is a leading EU-GMP vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio.

At SOMAÍ, we are building a leading global brand with the most robust pipeline of innovative cannabis-based therapeutics. We envision a world where people live a healthy lifestyle empowered by natural cannabis medicine.

SOMAÍ owns a state-of-the-art manufacturing facility, SOMAÍ Pharmaceuticals, and indoor cultivation NovaSoma in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets.

For more detailed information and investment opportunities, please reach out to us:

Email hello@somaipharma.eu

Phone +351 263 244 000

Address Lugar de Casal Pinheiro, Urbanização Pinheiros Park II, Block B., R. 13 de Maio 52, 2580-507 Carregado, Portugal

Opening hours Mon – Fri: 9:00 – 18:00

Please leave your request, and we will get in touch with you

Company News

SOMAÍ Pharmaceuticals and Canify Announce Their Partnership to Introduce a Cannabinoid-Based Product Line in Germany

December 21, 2023

SOMAÍ Pharmaceuticals announces a landmark three-year marketing & distribution agreement with Canify AG. This partnership signifies SOMAÍ Pharmaceuticals’…

SOMAÍ Pharmaceuticals Enters German Market with Strategic Partnerships Securing €10 Million 2-year Distribution Deal

December 14, 2023

SOMAÍ Pharmaceuticals announces its entry into the German market through partnerships with Canymed GmbH and Grünhorn, securing a…

Newsletter 1200 x 628 px 1200 x 628 px 1920 x 950 px 1

SOMAÍ Pharmaceuticals Partners with UK’s largest medical cannabis study T21 by Drug Science

December 12, 2023

SOMAÍ Pharmaceuticals is thrilled to announce partnering with the groundbreaking medical cannabis study, T21 (formerly Project TWENTY21). As…

SOMAÍ Pharmaceuticals Signs Manufacturing Contract with Canna Forest

November 28, 2023

SOMAÍ Pharmaceuticals has signed a manufacturing agreement with Canna Forest to produce EU-GMP-certified extracted cannabis APIs and products…

SOMAÍ Pharmaceuticals Receives EU-GMP Certification

September 1, 2023

SOMAÍ Pharmaceuticals Unipessoal LDA, the largest European pharmaceutical cannabis product manufacturer, is pleased to…

SOMAÍ Pharmaceuticals has renewed the partnership

July 26, 2023

According to this partnership, Lusófona will develop lab-scale formulations and perform corresponding stability testing. The collaboration…

SOMAÍ Pharmaceuticals Signs Supply Contract with Cosma Cannabis

June 12, 2023

SOMAÍ Pharmaceuticals has entered into a two-year supply agreement with a well-respected Polish distributor Cosma Cannabis and signed…

SOMAÍ Pharmaceuticals Collaborates with Clever Leaves

May 31, 2023

SOMAÍ Pharmaceuticals has entered into a five-year agreement with Clever Leaves Holdings Inc., a global medicinal cannabis company…